peptide corresponding to the C-terminal region (residues 192-211) of human invariant chain .' D 1 C 10 is an irrelevant murine monoclonal antibody used as a control . Rabbit anti-mouse immunoglobulin (RaMIg)' was purchased from Accurate Chemical & Scientific Corp . (Westbury, NY .)
Biosynthetic Labeling and Solubilization . Biosynthetic labeling with ['H]leucine, "SO .,, [ s5S]methionine, and ['H]methionine was done as previously described (6, 7) . In brief, cells were labeled at a density of 2 x 106 cells/ml for 5 h at 37°C in precursor-deficient media containing 250-500,uCi of the appropriate radiolabeled precursor . After washing, cells were solubilized either in PBS containing 0 .5% NP-40 or in 0 .05 M sodium acetate, 0 .15 M NaCl, 0 .5% Triton X-100, pH 6 .0 (associative DEAE starting buffer), containing protease inhibitors (6, 7) . The cell lysates were ultracentrifuged at 100,000 g for 60 min to remove insoluble debris .
Purification of the Class II-associated Proteoglycan. Under associative buffer conditions, the associative DEAE-buffer lysate was applied in batch to the anion-exchange resin DEAE-Sephacel (Pharmacia Inc ., Piscataway, NJ) at a ratio of 0 .1 ml of packed Sephacel per 10 8 cell equivalents . Unbound material was collected, and the DEAE-Sephacel was washed with 0 .2 M NaCI, 0 .05 M sodium acetate, 0 .5% Triton X-100, pH 6 .0 . Bound material was eluted with 0 .8 M NaCI, 0 .05 M sodium acetate, 0 .002% Triton X-100 (DEAE elution buffer) . After elution, the eluate was adjusted to 0 .2 M NaCI, pH 7 .4 .
Immunoprecipitation. Detergent iysates or DEAE-purified eluates were precleared (6, 7) and then reacted with monoclonal antibodies, or rabbit antiserum . Monoclonal antibody-antigen complexes were pelleted using protein A-Sepharose (Pharmacia, Inc .) which had been prearmed with RaMIg (RaMIg-protein A) . Rabbit antiserum-antigen complexes were pelleted with protein A-Sepharose .
Purification of the Class II-associated Proteoglycan under Dissociative Conditions . Antibody and radiolabeled molecules were eluted from the immunoprecipitates using DEAE-associative starting buffer containing 8 M urea (DEAE-dissociative starting buffer), and the eluates were applied batchwise to fresh DEAE-Sephacel . Unbound material was collected, and the DEAE-Sephacel was washed in DEAE-dissociative buffer containing 0 .2 M NaCl, Material bound to the DEAE-Sephacel was eluted with DEAE elution buffer .
Chondroitinase Treatment of the Class 11-associated Proteoglycan. The DEAE elution buffer containing the doubly purified chondroitin sulfate proteoglycan (CSPG) was diluted with three volumes of chondroitinase buffer (0 .05 M Tris, pH 6 .0, containing 0 .01 BSA) and divided into two aliquots . One aliquot was treated with chondroitinase AC (Miles Laboratories, Inc ., Elkhart, IN) (1 .5 U/ml) to yield the core protein of the proteoglycan, and the other was mock digested . In some experiments, chondroitinase ABC (Miles Laboratories, Inc .) was used in place of chondroitinase AC . Samples were incubated at 37'C for 2 h . The core protein or mock-digested proteoglycan was precipitated by the addition of TCA to a final concentration of 20% (wt/vol) . SDS-PAGE. For analytical or preparative SDS-PAGE, immunoprecipitates were eluted in or samples were adjusted to 0 .062 M Tris, 2 .0% SDS, 2% 2-ME, 10% glycerol, and 0 .001% phenol red, and then boiled for 2 .5 min . Samples were electrophoresed through a 1-cm 4% stacking gel and a 11 .5-cm 1 I % (except where indicated) running gel using a modification of the Laemmli-Maizel system (10, 11) . Gels were processed for autoradiography .
Trypsin Digestion. The bands of interest in the SDS-PAGE slab gel were localized by autoradiography . The pieces of gel containing the bands were excised, reswollen in 30% methanol/10% acetic acid, washed in distilled water, and then placed in 0 .5 ml of 0 .1 M NH 4 HCOs , pH 8 .2, containing 0 .1 ml of N-tosyl-t.-phenylalanine chloromethyl ketone ' O'Sullivan, D . M ., C . Wong, R . A . Houghten, and V . Quaranta . Identification of invariant chain-related components in la oligomers by antipeptide antisera. Manuscript submitted for publication .
'Abbreviations used in this paper: CSPG, chondroitin-4-sulfate proteoglycan ; NRS, normal rabbit serum ; RaMIg, rabbit anti-mouse immunoglobulin ; TPCK, N-tosyl-t .-phenylalanine chloromethyl ketone .
(TPCK)-trypsin (200 ug/ml) in 0 .001 N HCl) (Worthington Biochemical Corp ., Freehold, NJ) . The mixture was incubated for 30 min at 37°C, at which time 10 ul of 0 .4 M NH 4HCO3 , pH 8 .2, and an additional 0 .1 ml of TPCK-trypsin was added, and the incubation was continued overnight . The reaction was stopped by the addition of 0 .1 ml of 0 .8 N acetic acid . The gel pieces were removed by centrifugation, and the eluates were chromatographed on a C-18 reverse-phase column (Vydac, Hesperia, CA) using a gradient (see Results) of 0-50% acetonitrile (J . T . Baker Chemical Co ., Phillipsburg, NJ) in trifluoroacetic acid (Pierce Chemical Co., Rockford, IL) and a HPLC system (Waters Associates, Milford, MA) .
Reprecipitation of the CSPG and Its Core Protein. The mock-digested and chondroitinasetreated doubly purified CSPG containing the CSPG and its core protein respectively were each pretreated by immunoprecipitation with DIC10 and RaMIg-protein A . Aliquots of the pretreated samples were reacted with DIC10, 1800D2 .4, VIC-Y1, C351, or normal rabbit serum (NRS), and immunoprecipitation was accomplished using RaMIg-protein A, or protein A as appropriate . The immunoprecipitates were analyzed by SDS-PAGE using a 1 I % running gel .
Two-dimensional Gel Electrophoresis. The mock-digested, doubly purified CSPG and the chondroitinase-treated, doubly purified core protein were chromatographed on Sephadex G-25 in IEF elution buffer (8 M urea, 5% 2-ME, 2% ampholytes, pH 3 .5-10, [LKB Products, Gaithersburg, MD] and 0 .1 % NP-40) . The samples were then analyzed by twodimensional gel electrophoresis as previously described (6, 12 (13) . Chrondroitinase AC (1 .5 U/ml) was added to half of each preparation, and the samples were incubated at 37°C for 30 min . The cells were washed three times in PBS. Cell viability was >98% as judged by trypan blue exclusion . The cells were solubilized in PBS containing 0 .5% NP-40 . The lysates were ultracentrifuged and pretreated, and immunoprecipitates were prepared and analyzed by SDS-PAGE on 1 I % slab gels as described above .
Results
The strategy we used to characterize the core protein of the CSPG associated with human class II molecules was adapted ( Fig. 1 ) from the one successfully employed in the murine system (7) . In brief, [ s5 S]methionine-radiolabeled proteoglycans and their associated molecules were purified from lysates of Swei cells by their ability to be bound by DEAE-Sephacel . This first purification was performed under associative conditions to maintain the a#y-CSPG complex as a unit . Unbound material was collected, and then the DEAE-bound material that contained the a,dy-CSPG complex was eluted with 0 .8 M NaCI . After dilution, the a#y-CSPG complex was isolated from other proteoglycans in the eluate by specific immunoprecipitation with the murine anti-human invariant chain monoclonal antibody VIC-Y1 (5 and the bound fraction containing the CSPG was again eluted by 0.8 M NaCl . After dilution, the purified CSPG was treated with the chondroitin sulfate glycosaminoglycan-specific glycosidase, chondroitinase AC, to generate the CSPG core protein(s) . The core proteins were purified by SDS-PAGE and compared with the family of invariant chains by a number of biochemical and immunochemical analyses . Fig. 2 shows the SDS-PAGE analysis of the doubly purified [35 S]methioninelabeled CSPG before chondroitinase treatment (lane 4) . The CSPG migrates as a broad band with an Mr of 40,000-70,000 . Particularly notable is the absence of any bands corresponding to the a, ,Q, or y chains, similar to the finding in the murine system (7). The doubly purified CSPG represents^-19 .5% of the radioactivity immunoprecipitated from the associative DEAE-Sephacel-bound fraction, 0.25% of the radioactivity in the associative DEAE-Sephacel-bound fraction itself, and 0.014% of the radioactivity in the whole cell lysate . This degree of purification demonstrates the power of this simple three-step procedure.
The SDS-PAGE profile of the core protein (lane 5) obtained after chondroitinase treatment of the CSPG differs dramatically from that of the CSPG . The broad band in the Mr 40,000-70,000 region of the gel is no longer seen, demonstrating the efficacy of the chondroitinase treatment. Instead, a series of lower-Mr.
[s5S]methionine-labeled proteins are seen. The most intense of these bands migrates with an M, of^-38,000 (lane 5, arrow) . Less intense bands migrate with Mr of 46,000 and 28,000 (lane 5, arrowhead) . The finding of three protein bands generated after chondroitinase digestion of the CSPG suggested that the CSPG could have as many as three core proteins, or that the lower-Mr core proteins were partial degradation products of the larger .
To determine in a preliminary fashion if the generated core protein compo- These bands correspond to the y,, p4l, and p25 members of the family of invariant chain-related proteins . Although the CSPG core proteins (lane 5) were larger than the invariant chain proteins (lane 6), their periodicity was similar, suggesting a possible relationship between the two sets of proteins . This relationship was further explored by comparative two-dimensional gel analysis of the CSPG, its core proteins, and the invariant chain proteins (Fig. 3) . The CSPG migrates as two major species (Fig. 3A) , similar to the pattern seen for the murine CSPG (14) . The major component (bracket) was detected as a vertical band of fairly homogeneous pI of^"6.1, and Mr of^-40,000-70,000 . The second major component (brace) is seen as a diagonal spot of more heterogeneous pI (^"4.2-5 .0) and M, of^-50,000-60,000. A series of light spots (arrows) of pl 4 .6-5.8 and M^-38,000-40,000 is also observed . The intense high-M, acidic spots have not been identified, but for the most part they are unaffected by chondroitinase treatment (compare with Fig. 3B ) . Of note again is the absence of any detectable conventional invariant chain components in this doubly purified CSPG preparation.
The two-dimensional gel pattern of the core proteins (Fig. 3B ) released from the CSPG by chondroitinase treatment is quite distinct from that of the CSPG . The two major components of the CSPG are no longer seen. The most intense set of spots corresponding to the core proteins (bracket) is seen in the 38,000 Mr range of the gel, across a heterogeneous pI range (4.5-7.2). The most acidic of these spots (arrows) correspond exactly to the series of light spots seen in the two-dimensional gel analysis of the CSPG (Fig. 3A, arrows) but are now more intense. A second set of spots (curly bracket) is seen in the 28,000 Mr range of the gel . The most intense of these migrates in the pI range of 4.0-5.0 . No readily discernible set of core proteins in the M, 46,000 range was seen.
Two-dimensional gel analysis of the anti-invariant chain immunoprecipitate (Fig. 3 C) demonstrated the previously observed pattern (3, 5) . Comparison of the core proteins (B) with the invariant chain proteins showed that the 38,000 Mr set of core proteins (B, bracket) corresponded to the 31,000 Aset of invariant chain proteins (Fig. 3 C, bracket) , but migrated at a more acidic pl . The 28,000 M, set of core proteins (B, brace) shows little obvious correspondence to the 25,000 Mr set of invariant chain proteins (C, brace and arrowheads), and migrates in a more acidic pI range.
Although the two-dimensional gel analysis suggested a possible correspondence between the CSPG core proteins and invariant chain proteins, the results were far from conclusive . We therefore compared these sets of proteins by doublelabel tryptic peptide analysis. Pieces of gel containing the 38,000 M-species of core protein (Fig . 2, lane 5, arrow) and the 31,000 M, species of invariant chain (Fig. 2, lane 6, arrow) were excised, and combined. Similarly, pieces of gel containing the 28,000 M,. species of core protein and the 25,000 M,. species of FIGURE 3. Two-dimensional gel comparison of the CSPG, its core proteins, and invariant chain proteins. Aliquots of the material analyzed in lanes 4, 5, and 6 by one-dimensional gel electrophoresis were also analyzed by two-dimensional gel electrophoresis. The CSPG (A) migrates as two major components (bracket and brace), and several minor components (arrows). After chondroitinase digestion (B), the two major components are no longer seen . Instead, the core protein migrates as a series of spots of^-38,000 M, (bracket), the most acidic of which (arrows) correspond exactly to the four components (arrows) seen in A. In addition, a 28,000 Mr acidic core protein is seen (B, brace) . The invariant chain proteins (C) migrate as a major series of spots of 31,000 A two 25,000 M, spots (arrowheads) and an acidic 25,000 M* spot (brace) . The a and 0 chains coprecipitated with the invariant chain antibody are labeled. (Fig. 1, arrows) . (B) Comparison of the 18,000 M, core protein and p25 (Fig . 1, arrowheads) .
invariant chain (Fig. 2 , lanes 5 and 6, arrowheads) were excised and combined . The two sets of samples were subjected to trypsin digestion, and the resultant peptides were separated on a C-18 reverse-phase HPLC column using a gradient of 0-50% acetonitrile in 0.1% trifluoroacetic acid . The elution profiles are shown in Fig. 4 . The analysis of the larger Mr proteins is shown in Fig. 4A . 9-10 peptides are seen for each chain . Although there are some quantitative differences, virtually all of the peptides coelute, indicating the nearly complete structural identity of the major CSPG core protein and invariant chain . The analysis of the smaller-Mr set of proteins is seen in Fig. 4B . Again, nine peptides are observed for each chain, and virtually all of the peptides coelute. These results demonstrate the structural relatedness of these components . The Mr differences observed on one-and two-dimensional gels between the CSPG core proteins and the invariant chain proteins are most likely attributable to residual carbohydrate moieties on the core protein. Chondroitinase digestion of proteoglycans leaves at least the internal trisaccharide xylose-galactose-galactose on the core protein.
Comparison of the profiles in Fig. 4A and B demonstrates correspondence of the peptides of p25 with those of invariant chain (solid lines) and of the peptides of the 28,000 Mr core protein with those of the 38,000 Mr core protein (dashed lines) . These results indicate that in each case, the smaller-M, . species is clearly related to the larger-M, species. It is unclear if the smaller species is a partial degradation product of the larger, or is an alternatively processed form. In addition, a peptide map of p41 (data not shown) demonstrated its relatedness to p25 and y, .
The experiments above demonstrated the structural relatedness of the core protein(s) and invariant chain protein(s) . We next determined whether these proteins were antigenically similar. A ["S]methionine-labeled, doubly purified CSPG preparation was further purified by an additional passage over DEAESephacel under dissociative conditions to eliminate any possible contamination of the CSPG preparation with conventional invariant chain. Aliquots of a doubly purified 35 504-labeled CSPG preparation and the triply purified [35 S]methioninelabeled CSPG preparation were taken to test for reactivity with anti-invariant chain antibody . Half of the [s5S]methionine-labeled preparation was treated with chondroitinase to generate the core proteins . The samples were then subjected to a pre-precipitation step with RaMIg-protein A to remove any radiolabeled material which potentially could bind nonspecifically to the immunoprecipitates . The samples were then divided into aliquots and tested for reactivity with D 1 C 10, VIC-Y1, C351, and NRS. The results are shown in Figs. 5 and 6. The 35S04-labeled CSPG (Fig. 5) , the [35S]methionine labeled CSPG (Fig. 6A) , and the [35 5]methionine-labeled core proteins (Fig. 6B) were not isolated in the DIC10 or NRS immunoprecipitates, but were isolated with the VIC-Y1 and C351 anti-invariant chain reagents. These results indicated that the CSPG and its core protein bore epitopes recognized by anti-invariant chain antibodies. Of note, the VIC-Y1 antibody made against intact human invariant chain reacts far better with the 38,000 M, core protein than with the 28,000 M, species (Fig. 6A , lane VIC-YI ). In contrast, the C351 and antibody made against the C-terminal region synthetic peptide reacts with both the 38,000 and 28,000 A core protein species in proportion to their representation in the eluate . (Fig. 6A, lane 351) . This finding suggests that the 28,000 A species includes at least some of the amino acid residues present in the synthetic peptide (residues 192-211), but either does not have or does not efficiently present the epitope recognized by VIC-Y1 .
The absence of any conventional invariant chain in the [35 S]methionine labeled CSPG preparation is demonstrated in Fig. 6A , lane 1 (eluate) and is confirmed by the two-dimensional gel analysis of a doubly purified CSPG preparation shown in Fig. 3A . This finding indicates that the presence of the CSPG and its core proteins in the anti-invariant chain immunoprecipitates in this reimmunoprecipitation experiment is attributable to a direct reaction of these molecules with the FIGURE 5. "S04 -labeled CSPG can be reprecipitated with anti-invariant chain antibody . Doubly purified "S04-labeled CSPG was prepared from Swei cells as described in Materials and Methods. The "S04-labeled CSPG was precleared with RaMIg and protein A, and then aliquots were reacted with DICIO, VICY1, C351, or NRS, and immunoprecipitated with RaMIg-protein A or protein A.
antibody, and not to a possible association of these molecules with any invariant chain that potentially could have been contaminating the triply purified samples.
The CSPG purified from class II immunoprecipitates prepared using VIC-Y1 and the CSPG purified from class II immunoprecipitates prepared using 1800D2.4 have superimposable one-and two-dimensional gel patterns, indicating their identity (data not shown) . For quantitative reasons, the [s5S]methioninelabeled CSPG purified from the VIC-Y1 immunoprecipitate was used in the preceding experiments. Identical results to those shown in Fig. 5 were obtained with an "S04 -labeled CSPG purified from an 1800D2.4 immunoprecipitate (data not shown) . The results from the preceding experiments confirm the structural and antigenic identity of the human CSPG core protein and invariant chain .
In order to gain insight into a potential role of the CSPG in the biology of the class II molecules, we next addressed the question of where in the cell the CSPGclass II complex was located. Because of the known role of proteoglycans in intercellular (15) and cell matrix (16) interactions, we first determined whether the proteoglycan was associated with class II molecules at the cell surface. Intact cells were radiolabeled with [sH]leucine or asS04 for 5 h . After washing, the cells were divided into two aliquots. To detect cell surface class II molecules, one aliquot was reacted directly with antibody for 30 min, and then lysed in PBS containing 0 .5% NP-40 and a fivefold excess of unlabeled cells to bind any free remaining antibody sites. To detect total cellular class II molecules, the second aliquot of cells was lysed in PBS containing 0.5% NP-40, processed in the usual way, and then reacted with antibody . Immunoprecipitates were prepared using RaMIg-SaCI, and analyzed by SDS-PAGE . The results are shown in Fig. 7 .
['H]leucine-labeled class II molecules (top) are detected both from the total cell lysates (lane DR) and at the cell surface (lane DR). In addition, immunoprecipitates prepared after reaction of the antibody with cell surface class II molecules clearly contain "S04-labeled CSPG (Fig . 7, bottom, lane DR) . In each case, more material is immunoprecipitable from the cell lysates than from the cell surface. These results indicate that the CSPG is at least in part associated with cell surface class 11 molecules. Of note, similar results were obtained after only a 15-min pulse label (no chase) of "S04 indicating that this association of s5 SO 4-labeled CSPG with cell surface la is extremely rapid. However, these results do not directly determine whether the CSPG itself is expressed at the cell surface.
To address this last question, cells were labeled with [sH]leucine or "S04 for 3 h, washed, and then divided into two aliquots . One aliquot of intact cells was treated with chondroitinase AC to remove all cell surface proteoglycan, and the second aliquot was mock digested . Cell viability after chondroitinase digestion was >98% . After digestion, the cells were washed three times, and solubilized in Fig.  8 . Equal amounts of [3H]leucine-labeled DR molecules are precipitable from both the chondroitinase-and mock-digested samples. In contrast, 35 SO4-labeled CSPG is present in the sample prepared from mock-digested intact cells, but totally absent from the sample prepared from chondroitinase-treated intact cells. The residual 35 S04-labeled band seen after chondroitinase treatment is sulfated a chain. 3 These results indicate that virtually all the 35 S04-labeled class II-associated CSPG is accessible to chondroitinase, and therefore must be expressed on the cell surface.
One caveat in the above experiment is the possibility that even after extensive washing, chondroitinase remained on the intact cells. Solubilization by NP-40 would then allow intracellular proteoglycans to be digested by the enzyme, and any intracellular class II-associated CSPG would no longer be detectable . To address this possibility, unlabeled intact Swei cells were either chondroitinase treated or mock digested, and washed three times to remove the enzyme . An equal number of 35 SO4-labeled intact Swei cells was then added to each aliquot of unlabeled cells, the mixtures were solubilized by NP-40 detergent, and s Sant, A. J., M. Zacheis, T. Rumbarger, K. S. Giacoletto, and B. D. Schwartz . Human la a and ß chains are sulfated . Manuscript submitted for publication. incubated at 37'C for 30 min. Chondroitinase was added back to one aliquot of the lysate of 38 S04-labeled and mock-digested unlabeled cells, and the mixture was incubated at 37°C for 30 min. The processed lysates were then reacted with 1800D2.4 or D 1 C10 . Equal amounts of 35 SO4-labeled CSPG were precipitated from the lysates that contained the condroitinase-treated or mock-digested unlabeled cells (data not shown) . In contrast, no 35S04-labeled material was detected when chondroitinase had been added after solubilization . These results indicate that chondroitinase is not being retained on the intact cells after washing, and confirm the interpretation of the results of the previous experiment that virtually all the class 11-associated CSPG is present on the cell surface.
Discussion
The experiments presented here indicate that the human invariant chain (1'i) and its related components are the core proteins of the human class 11-associated CSPG . They thus establish that in humans, as in mice (7), the CSPG is an alternatively processed form of variant chain. Further, the results indicate that virtually all the class II-associated CSPG is present on the cell surface .
The purification method we used was modified from that used in the murine system (7), and involved three steps: associative affinity chromatography, immunoprecipitation, and dissociative affinity chromatography. This procedure resulted in a >7,000-fold purification of the class II-associated CSPG, based on [35S]methionine radioactivity. Removal of the glycosaminoglycan yielded the core proteins .
On one-dimensional gel analysis, three distinct core proteins were visualized. These migrated with Mr of 46,000, 38,000, and 28,000, and had the same periodicity as the p41, -y,, and p25 invariant chain proteins . Tryptic peptide analysis confirmed the identity of the 38,000 Mr core protein and 'Y1, and of the 28,000 Mr core protein and p25 . Although there was insufficient radioactivity of the 46,000 Mr core protein to prove identity of the 46,000 Mr core protein and p41 by tryptic peptide analysis, we believe that this is most likely the case. In addition, the peptide maps indicated the relatedness of p41, 'Y1, and p25, and of the 38,000 and 28,000 Mr core proteins. These results suggest at least two possibilities for the finding of several core proteins . First, each invariant chain species can be independently processed to a proteoglycan form. The individual invariant chain species may be generated either from distinct transcripts of a single invariant chain gene (17) or as the result of proteolytic degradation of a larger invariant chain species. Alternatively, only the larger forms of invariant chain (i .e., 7,, 72, 73 and p41) may be processed to a proteoglycan form, and then this proteoglycan is degraded to a smaller form of which the core protein is 28,000 Mr. Our data do not allow us to distinguish between these possibilities. However, either of these possibilities would account for the finding of two distinct populations of class II-associated proteoglycan on two-dimensional gel electrophoretograms.
Studies on other CSPG suggest that the attachment site of the chondroitinsulfate glycosaminoglycan is on a serine residue that is immediately succeeded by a glycine residue (18) . If this holds true for the class I1-associated CSPG, it would place the attachment site for the glycosaminoglycan at serine 202, the only serine in the human invariant chain sequence followed by glycine. This postulate would then suggest that each core protein bears only a single glycosaminoglycan, though the latter can vary in size . The cleavage of the 38,000 Mr core protein to the 28,000 M, core protein ( and presumably y,, to p25) would have to be either C-terminal to serine 202 or at the N terminus .
The derived amino acid sequence of invariant chain suggests it is a transmembrane protein with the C terminus on the outside of the cell (19, 20) . The attachment site at serine 202 would thus indicate the glycosaminoglycan is exposed on the cell surface. Our experiments demonstrating that the class II-associated CSPG present in intact cells is susceptible to chondroitinase digestion prove this hypothesis . The result of this experiment was somewhat surprising to us, however, in that it demonstrated that virtually all the class II-associated CSPG in the cell was exposed on the cell surface. This result suggests that the addition of the glycosaminoglycan to the invariant chain core protein must occur immediately prior to the transport of the CSPG to the plasma membrane . It also indicates that at least this form of invariant chain is on the cell surface.
Although some previous reports (4, (21) (22) (23) have noted the inability to detect invariant chain on the cell surface, other more recent reports (D . M. O'Sullivan, unpublished data, and 24) have indicated that cell-surface invariant chain can be detected . The ability to detect invariant chain on the cell surface undoubtedly depends on the ability of the antibody used to recognize an available epitope. If the CSPG is the only form of invariant chain present on the cell surface, the availability of the epitope may also be influenced by the presence of the glycosaminoglycan .
The presence of the CSPG form of invariant chain on the cell surface with class II molecules again raises questions regarding the function of the invariant chain/CSPG in the biology of class II molecules. In a previous report (7), we organized the potential functions of this molecule into three non-mutually exclusive areas: biosynthesis/targeting, turnover/recycling, and participation in class II-mediated intercellular events . The data in this and other recent reports do not at this time allow differentiation among these possibilities, but lend some support to each of them . Recent studies from one of our (25) and other (26) laboratories have demonstrated that chloroquine and monensin treatment of cells prevent the dissociation of the invariant chain from the a# heterodimer. These data were interpreted to suggest that a low pH processing step, presumably in a trans Golgi vesicle is responsible for the dissociation of the invariant chain from the a# heterodimer. Disruption of this step may therefore prevent the presumed final step in transport of the a,# heterodimer to the membrane (D . M. O'Sullivan, unpublished data, and 26). However, because these and other lysosomotropic agents also prevent the addition of glycosaminoglycan to core proteins (27, 28 , and S . Rosamond, unpublished observations), these data can also be interpreted to suggest that inhibition of the conversion of the invariant chain to its proteoglycan form prevents the dissociation of the invariant chain from the a,# complex, and possibly therefore the transport of the a,# heterodimer to the cell surface by the CSPG . If this latter interpretation is correct, it supports the role of the CSPG in targeting newly synthesized class II molecules to the plasma membrane . Additionally, if recycling of class 11 molecules is required for antigen processing and/or presentation, the CSPG could function to target recycled class II molecules back to the cell membrane . In this context, the structural and possible functional parallels between the invariant chain/CSPG and transferrin receptor have already been noted (7) .
The third possibility, that the class II-associated CSPG may participate in cellular interactions involving the immune response, receives support from the precedent for such participation by proteoglycans in other systems (15, 16) , and from our finding that virtually all the class II-associated CSPG is on the cell surface.
Transfection experiments are currently exploring the role of the invariant chain/CSPG in the expression and function of the class II molecules. These experiments may help differentiate among the potential roles of the invariant chain/CSPG, and should determine if this role is obligatory or facilitating in the biology of class II molecules.
Summary
The human class II-associated chondroitin sulfate proteoglycan (CSPG) was analyzed biochemically and immunologically to determine a possible relationship with the human invariant chain (-yi) and its related components . The CSPG was purified by a three-step procedure involving associative ion-exchange chromatography, immunoprecipitation, and dissociative ion-exchange chromatography . Treatment of the CSPG with chondroitinase revealed core proteins of MT 46,000, 38,000, and 28,000, with the 38,000 species most highly represented. Tryptic peptide analysis revealed identity of the peptides of the 38,000 Mr core protein and 7,, and of the 28,000 M r species and p25. The CSPG and its core proteins were shown to react directly with the mouse anti-human invariant chain monoclonal antibody VIC-Y 1 and a rabbit antiserum produced against a synthetic peptide corresponding to the C-terminal end of invariant chain . These results demonstrate that the invariant chain is the core protein of the class II-associated CSPG . In addition, virtually all the CSPG was shown to be present on the cell surface.
